Hand William R, Whiteley Joseph R, Epperson Tom I, Tam Lauren, Crego Heather, Wolf Bethany, Chavin Kenneth D, Taber David J
From the Department of Anesthesia & Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina; Georgetown University School of Medicine, Washington, DC; Medical University of South Carolina, Charleston, South Carolina; and Department of Public Health Sciences and Division of Transplant Surgery, Medical University of South Carolina, Charleston, South Carolina.
Anesth Analg. 2015 Mar;120(3):619-626. doi: 10.1213/ANE.0000000000000374.
Acute kidney injury (AKI) is a frequent complication of orthotopic liver transplantation (OLT). Hepatic failure pathophysiology and intraoperative events contribute to AKI after OLT. Colloids are routinely used to maintain intravascular volume during OLT. Recent evidence has implicated 6% hydroxyethyl starch (HES) (130/0.4) with AKI in critically ill patients.
We performed a retrospective cross-sectional analysis of electronic anesthesia records, surgical dictations, and perioperative laboratory results. Postoperative AKI incidence was determined by RIFLE (Risk Injury Failure Loss End-Stage) criteria. AKI was staged into Risk, Injury, and Failure based on change in serum creatinine from preoperative baseline to peak level by postoperative day 7. Uni- and multivariate analysis was used to evaluate the association between type of intraoperative colloid administered and AKI.
One hundred seventy-four adult patients underwent OLT and had complete records for review. Of these, 50 received only 5% albumin, 25 received both 5% albumin and HES, and 99 received only HES. Albumin-only, albumin and HES, and HES-only groups were otherwise homogeneous based on patient characteristics and intraoperative variables. There was a statistically significant linear-by-linear association between type of colloid(s) administered and AKI (Rifle Criteria-Injury Stage). Patients administered HES were 3 times more likely to develop AKI within 7 days after OLT compared with albumin (adjusted odds ratio 2.94, 95% confidence interval, 1.13-7.7, P = 0.027). The linear trend between colloidal use (5% albumin only versus albumin/HES versus HES only, ranked ordering) and "injury" was statistically significant (P = 0.048). A propensity-matched analysis also showed a significant difference in the incidence of AKI between the patients receiving albumin compared with HES (P = 0.044).
Patients receiving 6% HES (130/0.4) likely had an increased odds of AKI compared with patients receiving 5% albumin during OLT. These retrospective findings are consistent with recent clinical trials that found an association between 6% HES (130/0.4) and renal injury in critically ill patients.
急性肾损伤(AKI)是原位肝移植(OLT)常见的并发症。肝衰竭的病理生理学及术中情况可导致OLT术后发生AKI。胶体溶液常用于OLT术中维持血管内容量。近期有证据表明,6%羟乙基淀粉(HES)(130/0.4)与危重症患者的AKI有关。
我们对电子麻醉记录、手术记录及围手术期实验室检查结果进行了回顾性横断面分析。术后AKI的发生率依据RIFLE(风险、损伤、衰竭、丧失、终末期肾病)标准确定。根据术后第7天血清肌酐相对于术前基线水平至峰值水平的变化,将AKI分为风险期、损伤期和衰竭期。采用单因素和多因素分析评估术中使用胶体溶液的类型与AKI之间的关联。
174例成年患者接受了OLT手术,且有完整记录可供分析。其中,50例仅接受5%白蛋白,25例同时接受5%白蛋白和HES,99例仅接受HES。仅白蛋白组、白蛋白与HES组以及仅HES组在患者特征和术中变量方面具有同质性。所使用胶体溶液的类型与AKI(Rifle标准-损伤期)之间存在显著的线性关联。与白蛋白组相比,接受HES的患者在OLT术后7天内发生AKI的可能性高3倍(校正比值比2.94,95%置信区间1.13 - 7.7,P = = 0.027)。胶体溶液使用情况(仅5%白蛋白、白蛋白/HES、仅HES,按顺序排列)与“损伤”之间的线性趋势具有统计学意义(P = 0.048)。倾向匹配分析也显示,接受白蛋白与接受HES的患者之间AKI发生率存在显著差异(P = 0.044)。
与OLT术中接受5%白蛋白的患者相比,接受6% HES(130/0.4)的患者发生AKI的几率可能更高。这些回顾性研究结果与近期临床试验一致,后者发现6% HES(130/0.4)与危重症患者的肾损伤有关。